Microneedling for facial wrinkles: what a specific FDA clearance covers
A named microneedling system has FDA clearance for specified facial wrinkles in adults 22 or older with a Fitzpatrick I–III indication. Its small supporting study included one type V participant, but the clearance did not extend to darker types.
Microneedling may be offered for facial wrinkles, but its FDA status depends on the exact device and treated area. The Exceed system’s 510(k) indication covers specified glabellar, periorbital and cheek wrinkles in adults at least 22 years old with Fitzpatrick I–III skin. Its 48-person supporting study included one type V participant, yet the cleared indication did not extend beyond I–III. Without a sham-treated comparison, the study cannot prove that every pen, RF device, deeper line or skin type will achieve the same result.12
The word wrinkle can refer to lines seen only with expression, creases present at rest, sun-related texture, or folds caused by volume and tissue position. A procedure claim becomes useful only after the visible target and the intended outcome are named.
Match the wrinkle to the reviewed site
| Question | Why it matters | Record to request |
|---|---|---|
| Where is the concern? | The Exceed clearance names glabellar, periorbital and cheek areas | Exact treatment zone and the device's intended-use sentence |
| What type of line is it? | A surface-wrinkle endpoint is not the same as a deep structural fold | Baseline standardized photographs and outcome measure |
| Which device is offered? | Mechanical microneedling and RF microneedling have different technology and risks | Manufacturer, model and 510(k) number |
| Who was studied? | The 48-person study was predominantly Fitzpatrick I–III, with one type V participant | The cleared indication remains I–III; ask what evidence fits the person's skin and concern |
This is not an eligibility checklist to apply at home. It is a way to prevent the broad phrase “FDA-cleared microneedling for wrinkles” from hiding a mismatch between a particular study and the service being sold.
A clearance is not a head-to-head winner
The 510(k) establishes a legally marketed intended use for a named device; it is not a ranking against neuromodulators, lasers, resurfacing or other wrinkle treatments. The original facial-wrinkle study assessed 48 subjects after a series of procedures through about day 150. It did not include a sham or untreated control arm that would isolate the device effect from natural variation, skin care, photography and expectations.12
The result can support discussion of a limited observed improvement in that study. It cannot support a promise to erase wrinkles, a universal number of sessions, a comparative superiority claim, or durability beyond the follow-up observed. If a clinic cites a different microneedling study, compare model, needle system, treated area, skin types, outcome and control group before accepting the analogy.
RF is a separate intervention
Radiofrequency microneedling adds energy delivery to tissue puncture. FDA’s general microneedling page lists specific medical-device uses but does not turn an Exceed mechanical-device clearance into an RF-category approval. Device settings and operator training can materially change the procedure. The RF safety guide addresses that extra exposure.3
The under-eye device guide examines a separate narrower periorbital device and evidence record. A general facial-wrinkle consultation should not borrow that article’s product claim, nor should an under-eye offer borrow Exceed’s cheek data without checking the exact indication.
Define a result that can be checked
Ask the provider to identify one or two lines or zones and the change it expects. Agree on standardized photographs or another documented measure, the follow-up interval, and how pigment, irritation, infection or an unexpectedly poor result will be handled. FDA notes possible adverse effects and the importance of a trained provider; a polished before-and-after gallery alone cannot substitute for the product and outcome record.3
At a microneedling practice consultation, bring the exact concern and ask: “Which device’s clearance covers this site and population, and which study supports the result you are describing?” The answer should be an exact record, not a procedure-category slogan.
Sources
- U.S. Food and Drug Administration. Exceed Microneedling System 510(k) summary, K180778. The device-specific clearance concerns glabellar, periorbital and cheek wrinkles in adults at least 22 with Fitzpatrick I–III; the study included one type V participant but the indication did not expand. Accessed .
- PubMed / original prospective study. Microneedling for facial wrinkles: clinical and patient assessments. Original 48-person uncontrolled study followed wrinkle appearance to day 150; without a sham comparator it cannot establish superiority or isolate expectancy and time effects. Accessed .
- U.S. Food and Drug Administration. Microneedling devices. FDA's consumer overview distinguishes medical-device uses, general risks and device-specific labeling. Accessed .